Rescue of dystrophic skeletal muscle in mdx and utrophin/ dystrophin-deficient (dko) mouse models by reintroduction of dystrophin has validated gene therapy as a potential therapeutic approach for Duchenne muscular dystrophy. However, the size of the dystrophin gene exceeds the capacity of adeno-associated viral (AAV) vectors. Dystrophin provides a mechanical link at the muscle membrane by direct binding of its amino-terminal and cysteine-rich domains to actin and a transmembrane protein complex, respectively. It has not been investigated whether restoration of these two tethering functions by two separate dystrophin molecules is sufficient to prevent dystrophic pathologies. We examine the effect of coexpression of the amino-terminal and cysteinerich domains from separate dystrophin transgenes, Dcys and Dp71, on the dystrophic phenotype. Expression of individual dystrophin domains from multiple vectors would effectively expand AAV capacity. Although both Dcys and Dp71 colocalize at the membrane, there is no improvement of dystrophic pathology. The fiber-type and neuromuscular junction abnormalities of dko mice that are ameliorated by the Dcys transgene are not further improved or disrupted by Dp71. Separate truncated dystrophins, which together restore all protein interactions and scaffolding for signaling molecules, are not sufficient to ameliorate the dystrophic phenotype and therefore dystrophin domains in trans cannot be used to increase the effective cloning capacity for AAV-mediated gene therapy. Gene Therapy (2006) 13, 744-751.
Introduction
Duchenne muscular dystrophy (DMD) is a recessive X-linked disorder that affects 1:3500 newborn males. The patients exhibit severe, progressive muscle weakening rendering them wheelchair bound in their early teens and they generally succumb to cardiac or respiratory failure in their early twenties. 1, 2 The disease is caused by the lack of functional dystrophin, a large cytoplasmic membrane-associated protein that localizes around the entire muscle fiber membrane and is concentrated at the neuromuscular junction (NMJ). [1] [2] [3] Dystrophin is made up of four structural domains, an amino(N)-terminal domain, a central rod domain, a cysteine-rich domain, and a carboxy(C)-terminal domain (Figure 1a) . 4 The N-terminal domain binds to filamentous actin, and the cysteine-rich domain is critical for binding and localization of the dystrophin-associated protein complex (DAPC), a group of integral and peripheral membrane proteins that form a link with laminin in the extracellular matrix. [5] [6] [7] This combination of binding abilities of dystrophin allows it to provide a mechanical link between the actin cytoskeleton and the extracellular matrix. In this way, dystrophin acts to protect the integrity of the muscle membrane from the repeated stress associated with cycles of contraction. 6 Dystrophin and the DAPC have also recently been implicated in functioning as a scaffold for signaling proteins. 8, 9 Two mouse models have been used to study dystrophin and its role in skeletal muscle. The most widely used mdx mouse contains a point mutation that results in the lack of functional dystrophin. 10 ,11 mdx mice exhibit dystrophic muscle pathology including fibrosis, inflammation, variation in myofiber size, and cycles of degeneration and regeneration evidenced by the presence of an increased number of centrally nucleated fibers. 12, 13 Despite this underlying muscle pathology, mdx mice do not show signs of extreme muscle weakness or impaired movement and live a normal mouse lifespan.
The second mouse model, double knockout (dko), is lacking dystrophin as well as the homologous protein utrophin. These mice exhibit the skeletal muscle pathology characteristic of dystrophic muscle. In addition, dko mice display outward signs similar to DMD including small stature, slack posture, abnormal waddling gait, labored breathing and premature death. They also exhibit a progressive muscle weakening similar to that of DMD patients. 14 Studies on dko mice have also evidenced a role for dystrophin in biochemical and structural properties of skeletal muscle. These mice exhibit an absence of postsynaptic folding at the NMJ and an irregular, discontinuous structure of acetylcholine receptor (AChR) localization. This disorganization is in contrast to wild-type (C57) NMJ structure that is highly ordered and continuous.
15 C57 and mdx muscle displays a patchwork of oxidative and glycolytic fibers, whereas dko muscle undergoes a fiber-type switch to almost exclusively oxidative fibers. 15 This fiber-type disproportion is also observed in DMD patients. 16 Studies on the mdx and dko mouse models of DMD have determined that the reintroduction of dystrophin rescues all of the associated dystrophic phenotypes. 15, 17, 18 Gene therapy, therefore, is being explored as a potential treatment option for DMD patients. The major challenge of applying gene therapy to DMD is that current adenoassociated viral (AAV) vectors contain a cloning capacity that is unable to support the large cDNA of the dystrophin gene (reviewed in Athanasopoulos et al. 19 ).
Thus, a great body of transgenic and patient data has been analyzed in an attempt to pare down what domains of dystrophin are absolutely essential for function.
Two of the truncated dystrophin transgenes that have identified critical functions of dystrophin are Dp71 and D64-67, which lacks exons 64-67 and is hereafter referred to as Dcys. Dp71 is a naturally occurring dystrophin isoform expressed in non-muscle tissue. 20 This 71 kDa protein is composed of the cysteine-rich and C-terminal domains of dystrophin, but lacks the N-terminal actinbinding domain and the central rod domain. 21 This Cterminal version of dystrophin is able to restore members of the DAPC to the membrane but is unable to correct any of the dystrophic muscle pathology present in mdx or dko mice (Figure 1) . 15, 21 The Dcys form of dystrophin contains an intact N-terminal actin binding domain, central rod domain, and C-terminal domain, but lacks the cysteine-rich domain, and therefore the ability to associate with members of the DAPC. Expression of this transgene results in the loss of the DAPC from the membrane and is unable to rescue the characteristic dystrophic muscle pathology ( Figure 1) . 7, 15 While Dcys/ dko mice are still outwardly dystrophic, expression of Dcys dystrophin is sufficient to prevent the structural abnormalities of the NMJ and the fiber-type disproportion in dko mice. Expression of Dp71 has no affect on these structural and biochemical properties of muscle. 15 These data were the first to show in vivo a function of dystrophin that did not require reassociation with F-actin and the DAPC.
It has previously been shown that microdystrophins, containing intact N-terminal and cysteine-rich domains and a truncated rod domain, but lacking the C-terminal domain, restore the DAPC to the membrane and are sufficient for preventing muscle degeneration and weakness in mdx mice. 22 However, it has not been investigated whether restoration of binding to actin and restoration of the DAPC to the skeletal muscle membrane by independent dystrophin molecules is sufficient to prevent dystrophic pathologies. The Dcys protein contains an intact N-terminal domain and is capable of binding to actin. The Dp71 protein contains an intact cysteine-rich domain and is capable of restoring localization of all members of the DAPC to the membrane. 7, 21 In the work presented here, the coexpression of the Dp71 and Dcys dystrophin proteins was enlisted to answer the question of whether the presence of all domains of dystrophin in trans are able to rescue any of the skeletal muscle pathologies present in dko mice. This approach would allow two vectors to carry the transgene, effectively expanding the cloning capacity of currently available AAV vector systems. Although the two transgene products were localized together at the membrane and therefore restored all protein interactions and signaling molecules that use the DAPC as a scaffold, an improvement of the dystrophic muscle pathology was not observed. In addition, we determined that the NMJ and fiber-type abnormalities that have been shown to be corrected by the introduction of the Dcys transgene are not further improved or disrupted by the additional presence of Dp71 (summarized in Figure 1b) . These results have implications for gene therapy and DMD because they support that coexpression of smaller overlapping portions of dystrophin in trans is not an option for reintroduction of the dystrophin gene. . This protein complex also includes a-DG and the sarcoglycans (SG). Dcys dystrophin maintains the N-terminal, rod, and C-terminal domains but lacks the cysteine-rich domain and therefore cannot restore the DAPC to the membrane. Dp71 dystrophin contains intact cysteinerich and C-terminal domains rendering it sufficient to restore the association with the DAPC, but lacks the N-terminal and rod domains, which prevents its association with the actin cytoskeleton. (b) Summary of localization of dystrophin transgenic protein products and members of the DAPC to the sarcolemma in Dcys/ dko, Dp71/dko, and Dcys + /Dp71 + /dko (+/+) mice. A rescue of dystrophic pathology is not observed in any of these mice, however Dcys and +/+ mice do exhibit a restoration of fiber-type ratio and the rescue of NMJ abnormalities of the dko phenotype.
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Results
Dcys and Dp71 dystrophin proteins localize to the membrane in +/+ mice mdx utrn +/À mice carrying the Dcys transgene were crossed with mdx utrn +/À mice carrying the Dp71 transgene in order to obtain mice positive for both transgenes on an mdx or dko background. Skeletal muscle from these Dcys + and Dp71 + mice (+/+) express overlapping dystrophin proteins that together provide all dystrophin domains ( Figure 1a ). Western blot analysis on total muscle protein from +/+ dko mice was performed with a dystrophin C-terminal antibody that recognizes both the Dcys and Dp71 proteins as well as endogenous dystrophin protein. The +/+ dko mice contain both a 410 kDa product, representing Dcys and a 71 kDa product, representing Dp71 (Figure 2a ). These two protein products were also observed in total muscle protein from +/+ mdx mice (data not shown). The single transgenic positive dko littermates were used as positive controls for the product sizes. A 427 kDa protein representing full-length dystrophin is present in samples from C57 quadriceps and dystrophin is absent from mdx and dko samples ( Figure 2a ). The Dcys and Dp71 protein products are present in the +/+ mdx (data not shown) and the +/+ dko mice at levels comparable to the single transgenic littermates (Figure 2a) . Thus, neither transgenic dystrophin protein is out competing or preventing the expression of the other. In addition, these levels are at least equivalent to endogenous dystrophin in control C57 muscle (Figure 2a) .
We next wanted to determine whether the Dcys and Dp71 protein products are present at the membrane. Membrane protein-enriched samples were prepared from Dcys, Dp71, +/+ dko, and +/+ mdx mouse quadriceps and analyzed by Western analysis with the same C-terminal dystrophin antibody. We observed that the 410 and 71 kDa products are enriched in the Dcys and Dp71 samples, respectively. Both transgenic dystrophin proteins are also observed in the +/+ dko and +/+ mdx membrane protein-enriched samples (Figure 2b and data not shown). Thus, both dystrophin products are localized together at the membrane in these mice at levels comparable to their single transgenic littermates.
To further confirm the localization of Dp71 and Dcys to the skeletal muscle membrane, as well as determine the uniformity of localization around entire muscle fibers, we analyzed mouse quadriceps cross-sections by immunofluorescence. An N-terminal antibody that recognizes the Dcys transgene as well as endogenous dystrophin shows that the Dcys protein is localized around the entire muscle membrane similar to wild type in both Dcys and +/+ samples (Figure 3a) . A second antibody, raised against the dystrophin C-terminus, recognizes both transgenes and shows that all dystrophin protein present in the +/+ muscle is localized to the membrane (Figure 3a ). Each antibody also shows membrane localization of endogenous dystrophin in control C57 muscle as well as the absence of dystrophin in mdx and dko samples (Figure 3a) .
Trans introduction of dystrophin domains is unable to rescue dystrophic muscle pathology
Once we established a line of mice expressing both the Dcys and Dp71 transgenes and confirmed the localization of these proteins to the membrane, we examined the effect of this trans introduction of overlapping dystrophin proteins on aspects of the dystrophic muscle phenotype. Overtly, +/+ dko mice are indistinguishable from their single transgenic or non-transgenic dko counterparts. They exhibit all of the aforementioned signs of DMD including small stature, curvature of the spine, labored breathing, and abnormal waddling gate (data not shown). 14 Next we analyzed the overall skeletal muscle pathology of the +/+ mdx and +/+ dko mice. Hematoxylin and eosin staining of mouse quadriceps sections revealed that the +/+ muscle morphology was characterized by variation in fiber size, regions of degenerating fibers, inflammation, infiltration of connective tissue, as well as muscle fibers containing centrally located nuclei indicating ongoing regeneration (Figure 3a) . These features were also observed in the single transgenic and nontransgenic dko muscles as well as mdx muscles ( Figure  3a) and are comparable to the published characteristics of dystrophic muscle. [12] [13] [14] In order to quantify any effect of the combination of the Dcys and Dp71 proteins on muscle regeneration in mdx or dko mice, the percentage of total muscle fibers containing central nuclei was determined for mice of each genotype. +/+ dko and +/+ mdx samples contain an average of 88.2 and 90.1% centrally nucleated fibers, respectively (Table 1) . These figures are not statistically different from the mdx, dko, Dcys, and Dp71 littermates examined in this study ( Table 1) .
The presence of Dp71 has been shown to be sufficient to establish the connection between dystrophin and members of the DAPC as evidenced by their restoration to the muscle membrane, while Dcys dystrophin is not sufficient to accomplish this function. 7, 21 We next wanted to determine whether the DAPC was restored to the sarcolemma in +/+ mice, in the presence of both Dp71 and Dcys dystrophin. Immunofluorescence staining with an antibody raised against b-dystroglycan (DG) revealed Dystrophin domains in trans are not additive KL Gardner et al that this protein is restored to the membrane in +/+ mdx and +/+ dko mice (Figure 3b) , suggesting that the Dcys protein does not disrupt the DAPC protein associations of the Dp71 protein. Membrane localization is also observed in C57 and Dp71 samples, but is absent from mdx, dko, and Dcys mice as expected (Figure 3b) . Thus, the link between dystrophin and the extracellular matrix via the DAPC appears to be restored in +/+ mice, and the Dcys protein does not exert a dominant negative effect.
Coexpression of Dcys and Dp71 results in Dcys-like correction of fiber-type and NMJ abnormalities of dko mice
We next wanted to examine the biochemical and structural properties of muscle that are altered in dko mice. NADH staining was used to examine the effect of trans expression of overlapping dystrophin proteins on the fiber-type abnormality of dko muscle. +/+ dko mice exhibit a patchwork of stained oxidative fibers and unstained glycolytic fibers reminiscent of control and Dystrophin domains in trans are not additive KL Gardner et al mdx mice (Figure 4a ). Dcys expression has previously been shown to prevent the fiber-type abnormality in dko mice, while expression of the Dp71 protein isoform has no effect on this phenotype (Figure 4a ). 15 Thus, the presence of the Dcys protein in the +/+ mice is able to functionally correct the fiber-type problem and the presence of Dp71 does not disrupt this Dcys function.
Dko mice exhibit structural abnormalities of the NMJ characterized by an irregular and discontinuous localization of AChR at the postsynaptic membrane ( Figure  4b) . 15 This phenotype is in contrast to the continuous, highly ordered AChR clustering at NMJs present in C57 muscle (Figure 4b) . mdx mice do exhibit some discontinuous NMJs, however, they maintain a significant percentage that are ordered and continuous. We have previously shown that Dcys dystrophin restores dko muscle to a percentage of continuous NMJs similar to mdx.
15
Expression of Dp71 has no effect on this abnormality of dko muscle. 15 a-Bungarotoxin staining of longitudinal sections of quadriceps indicates that +/+ dko mice contain a mixture of continuous NMJs and the irregular, discontinuous ones associated with dko muscle (Figure 4b) . Thus, it appears that the presence of the Dcys protein product is sufficient to ameliorate the NMJ structural integrity, and that the additional presence of Dp71 does not further improve or worsen this parameter.
Discussion
We established a population of mice expressing overlapping truncated dystrophin proteins that are localized to the skeletal muscle membrane. Despite this trans introduction of all functional domains of dystrophin, +/+ dko mice present the outward characteristics of their single and non-transgenic counterparts similar to DMD patients, and +/+ mdx and +/+ dko mice have no improvement of the characteristic dystrophic muscle pathology. +/+ dko mice also exhibit a Dcys-like correction to the NMJ and fiber-type abnormalities specific to dko, indicating that the additional presence of Dp71 does not aid or interfere in this regard.
It has previously been shown that the reintroduction of full-length dystrophin results in complete reversal of dystrophic muscle pathology. 15, 17, 18 These data support gene therapy as a possible strategy for treatment of this devastating disease. AAV vectors have several advantages over other potential viral gene therapy vectors including eliciting a minimal immunogenic response and extensive cell and tissue tropism. The disadvantage of this vector system is that it has a limited transgene capacity of less than 5 kB (reviewed in Athanasopoulos et al. 19 ). This limitation greatly complicates the use of AAV for diseases such as DMD that involve large genes. Several groups have been studying the effects of miniand microdystrophin transcripts on dystrophin muscle pathology in an attempt to pare down the 14 kB transcript into the smallest dystrophin capable of repairing the dystrophic muscle pathology; [22] [23] [24] (reviewed in Athanasopoulos et al. 19 ). Specific expression of the transgene in skeletal and cardiac muscle tissue requires muscle-specific promoters and further restricts the space for a dystrophin transgene in the small cloning capacity of the AAV vector system. Attempts to expand the AAV capacity, including trans-splicing of nonoverlapping transgene halves and overlapping vector systems based on homologous recombination have established the ability of muscle to take up vectors provided by two simultaneously introduced AAV systems and are awaiting further exploration. Dystrophin domains in trans are not additive KL Gardner et al
25-28
In the work presented here, we used the previously described Dcys and Dp71 transgenic mouse lines to answer the question of whether trans introduction of overlapping dystrophin molecules is able to rescue any of the signs associated with DMD. This strategy would allow necessary genetic information to be introduced by two or more vectors, thereby providing an approach to effectively expand the cloning capacity of currently available AAV vector systems. Despite the fact that all functional domains of dystrophin were expressed in trans and the Dcys and Dp71 proteins localized to the membrane, no improvement of the dystrophic muscle pathology was observed. Although it has previously been shown that N-and C-terminal dystrophin constructs can localize independently to the mdx muscle membrane, 29 the data presented here are the first to show the colocalization of dystrophin proteins separately containing actin-binding and DAPC-binding regions.
Dystrophin and the DAPC have recently been shown to interact with molecules involved in signaling pathways including nitric oxide synthase, Grb2, MEK2, and Erk. 8, 9 Therefore, these results also suggest that restoration of the dystrophin-associated scaffold for signaling molecules in the absence of dystophin's mechanical link is not sufficient to ameliorate any of the dystrophic pathology.
The results presented here have implications for gene therapy because they show in vivo that trans introduction of smaller overlapping portions of dystrophin is not an option for reintroduction of the dystrophin gene. For successful gene therapy as a therapeutic approach for DMD, it will be necessary to introduce the required portions of dystrophin in the same molecule. Thus, work with microdystrophins and the systems based on transsplicing and homologous recombination will remain the focus as possible routes for successful gene therapy treatment in DMD patients. While trans introduction of overlapping proteins was unsuccessful for the rescuing of the dystrophic phenotype characteristic of DMD, it may provide an approach for expanding the cloning capacity of AAV viral system in the case of a disease in which protein domains encoded by a large gene can function independently.
Materials and methods
Mice mdx utrn +/À mice with a Dcys dystrophin transgene (missing exons 64-67) were mated to mdx utrn +/À mice with a Dp71 transgene to generate mdx utrn À/À (dko), mdx utrn +/+ (mdx), Dcys/dko (Dcys), Dp71/dko (Dp71), Dcys + Dp71
+ (+/+) mdx, and (+/+) dko mice. Polymerase chain reaction was used to genotype all mice for the utrophin knockout allele and the presence of each dystrophin transgene as previously described. 14, 15 Wildtype C57Bl/10 (C57) mice were maintained as a separate inbred line. Quadriceps were dissected from 8 to 10-week-old mice and frozen in liquid nitrogen for Western analysis, frozen in OCT (VWR, West Chester, PA, USA) on liquid nitrogen-cooled isopentane for immunohistochemistry and histology experiments, or fixed for NMJ analysis as described below. Quadriceps muscles were used since both transgenes are expressed in this muscle at fairly even levels equivalent to normal dystrophin. The Dcys dystrophin protein is expressed at much lower levels in other limb muscles and is barely expressed in the diaphragm. 15 Mice were treated in accordance with the Institutional Laboratory Animal Care and Use Committee.
Immunoblots
Quadriceps from 8 to 10-week-old C57, mdx, dko, Dcys, Dp71, +/+ mdx, and +/+ dko mice were homogenized in Newcastle buffer (75 mM Tris pH 6.8, 3.8% sodium dodecyl sulfate (SDS), 4 M urea). Total protein concentration was determined by Dc protein assay (Bio-Rad, Richmond, CA, USA). Proteins (50 mg) were separated on 6 or 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gels electrophoresed at 80 V. Proteins were subsequently transferred to nitrocellulose membrane (Schleicher and Schuell Bioscience, Keene, NH, USA) via a Bio-Rad wet transfer system for 120 or 60 min. The membranes were blocked for 2 h in 5% nonfat dry milk containing 1% normal goat serum (NGS) in Tris-buffered saline plus 0.1% Tween 20 (TBST). The membranes were incubated for 2 h with Dys-2 mouse anti-dystrophin antibody (Novocastra, Newcastle upon Tyne, UK) diluted 1/100 in TBST + 1% NGS. After washing of unbound primary antibodies, the blots were incubated for 1 h in HRP-conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA), diluted 1/10 000 in TBST+1% NGS. After a final wash, the bound antibodies were detected by ECL chemiluminescence (Amersham Bioscienes, Little Chalfont, UK).
Preparation of membrane protein-enriched samples
Quadriceps from 8 to 10-week-old Dcys, Dp71, +/+ mdx, and +/+ dko mice were homogenized in 20 mM sodium pyrophosphate, 20 mM sodium phosphate monobasic, 1 mM MgCl 2 , 303 mM sucrose, 0.5 mM EDTA, 50 mM NaF, and protease inhibitors. Homogenate was centrifuged at 6600 g for 1 min. The resulting supernatant was removed and centrifuged at 10 000 g for 30 min. The supernatant was removed and centrifuged at 100 000 g for 2 h. The membrane-enriched protein pellet was resuspended in 75 mM Tris pH 7.5, 1 mM KCl, 1 mM MgCl 2 , 0.5 mM EDTA, 50 mM NaF, and protease inhibitors. SDS was added to a final concentration of 1% before total protein concentration was determined and immunoblotting was performed as described above.
Immunohistochemistry
Immunohistochemistry was performed on unfixed 8 mm quadriceps cryosections from 8 to 10-week-old C57, mdx, dko, Dcys, Dp71, +/+ mdx, and +/+ dko mice. Sections were equilibrated in potassium phosphate-buffered saline (KPBS) and subsequently blocked in 1% gelatin in KPBS for 15 min. Following blocking, sections were washed and incubated with N-terminal rabbit antidystrophin (1/500), 30 , Rb18 C-terminal rabbit antidystrophin (1:50 000) 21 (kind gift from JS Chamberlain), or rabbit anti-bDG 31 primary antibody diluted in KPBS+0.2% gelatin+1% NGS. Sections were washed again and incubated in Cy3-conjugated goat anti-rabbit (Jackson ImmunoResearch) or FITC-conjugated goat anti-rabbit (Jackson ImmunoResearch) secondary antibody in KPBS +0.2% gelatin + 1% NGS. Images were Dystrophin domains in trans are not additive KL Gardner et al obtained on a Nikon Eclipse 800 with a SPOT-RT slider digital camera and SPOT software.
Skeletal muscle morphology and central nuclei counts
Hematoxylin and eosin staining was performed on unfixed 8 mm quadriceps cryosections from 8 to 10-week-old C57, mdx, dko, Dcys, Dp71, +/+ mdx, and +/+ dko mice using standard methods. In all, 2-5 animals were analyzed from each genotype, including five +/+ dko mice. Centrally nucleated fibers were recorded as a percentage of total fibers (minimum of 250) counted for each mouse. These individual percentages were averaged to obtain the percentage of centrally nucleated fibers for each genotype.
NADH staining
NADH staining was performed on unfixed 8 mm quadriceps cryosections from 8 to 10-week-old C57, mdx, dko, Dcys, and +/+ dko mice. Sections were incubated in 0.2 M Tris pH 7.4, 1.5 mM b-NADH-reduced form disodium salt (Sigma, St Louis, MO, USA), and 1.5 mM nitro-blue tetrazolium (Sigma) for 30 min at 371C. Sections were rinsed for 2 min each in 30, 60, 90, 60, and 30% acetone. Images were obtained on a Nikon Eclipse 800 with a SPOT-RT slider digital camera and SPOT software.
NMJ immunohistochemistry
Quadriceps from 8 to 10-week-old C57, mdx, dko, Dcys, and +/+ dko mice were fixed for 1 h in 1% paraformaldehyde in KPBS. Tissues were soaked in 20% sucrose overnight and embedded into OCT and frozen on liquidnitrogen-cooled isopentane. Cryosections (30 mm) were prepared and stored at À801C until use. Slides were thawed and equilibrated in KPBS for 7 min. Sections were wash in 0.1 M glycine in KPBS for 1 h and subsequently permeabilized in 0.5% Triton X-100 in KPBS for 5 min on ice. Following washing, sections were blocked in 1% gelatin in KPBS for 1 h. Sections were incubated in Alexa 488-conjugated a-bungarotoxin (Molecular Probes, Eugene, OR, USA) diluted 1/200 in KPBS + 0.2% gelatin for 3 h. Sections were washed to remove any unbound toxin. Images were obtained on a Nikon Eclipse 800 with a SPOT-RT slider digital camera and SPOT software.
